In pharmaceutical manufacturing, compliance is not simply a matter of maintaining the right documents. Every deviation, unresolved investigation, unqualified piece of equipment, incomplete procedure, or weak change-control process can create consequences that extend from the manufacturing floor to regulatory inspection. As pharmaceutical companies expand production capacity and adopt increasingly complex technologies, the challenge is becoming less about documenting individual quality activities and more about ensuring that the entire system remains visible, connected, and inspection-ready.

This challenge becomes particularly significant during the development of new manufacturing facilities and pilot plants. Equipment must progress through Design Qualification, Installation Qualification, Operational Qualification, and Performance Qualification, while engineering, quality, procurement, and regulatory teams coordinate their responsibilities. When these activities remain separated into individual documents or departmental workflows, problems can remain hidden until they become project delays or compliance risks.

It is within this environment that Snehal Godse, a Documentation Specialist and Quality Specialist in R&D at InvaGen Pharmaceuticals, a Cipla subsidiary, has expanded the traditional boundaries of pharmaceutical documentation work. Her approach has centered on connecting quality systems with manufacturing readiness rather than treating compliance documentation as an isolated administrative function.

One of the clearest examples is her work on InvaGen’s Greenfield CAPEX pilot plant. Snehal designed and built a consolidated equipment qualification lifecycle tracker covering 17 critical pieces of process equipment for the MDI/inhalation pilot line. The tracker brings Design Qualification, Installation Qualification, Operational Qualification, and Performance Qualification into a single framework while also incorporating procurement and budget status, ownership, deadlines, and readiness information.

The significance of the approach lies in what it changes about qualification management. Instead of treating DQ, IQ, OQ, and PQ as sequential phases owned by different groups, the framework provides engineering, quality, and procurement teams with a shared view of equipment readiness. It can expose issues such as incomplete design inputs, missing risk assessments, documentation gaps, or procurement blockers before they become larger problems for the project.

Snehal’s work also goes beyond creating a project tracker. She has drafted and executed IQ/OQ/PQ protocols and FAT/SAT activities for critical process equipment, while also working across deviation investigations, CAPA management, OOS/OOT investigations, FMEA/FMECA risk assessments, change control, batch-record review, SOP authoring, technology transfer, and registration-batch manufacturing. These responsibilities place her at the intersection of quality systems, manufacturing operations, and regulatory requirements.

That cross-functional position is important because pharmaceutical quality problems rarely exist within one department. An equipment qualification issue can involve engineering, quality assurance, procurement, documentation, and manufacturing simultaneously. Snehal’s tracker attempts to make those relationships visible rather than allowing each function to manage only its own portion of the process. She describes this as a shift from completing individual quality tasks toward designing the systems through which the work itself is organized.

Her responsibilities also extend into the regulatory consequences of manufacturing readiness. She supports technology transfer and regulatory batch manufacturing and registration with the FDA for inhalation MDI products. Her quality responsibilities include activities that directly affect whether manufacturing and products can proceed under regulated conditions, including OOS/OOT resolution, equipment qualification, CAPA, and change control.

The broader direction of her work is increasingly connected to another emerging challenge: how artificial intelligence can be introduced into highly regulated pharmaceutical environments without weakening accountability. Snehal has been developing expertise in AI governance within GxP environments, an area that brings together AI oversight with the validation, documentation, and regulatory expectations already embedded in pharmaceutical quality systems.

That interest has also shaped her external contributions. Her peer-reviewed paper, A Cross-Functional Perspective on Scientific Collaboration, Regulatory Compliance, and Quality System Integration, was published in the American Journal of Technology in 2026. She has also worked on an IEEE-format manuscript addressing AI governance in GxP environments. Her stated focus is on connecting AI governance and quality-system principles with the practical validation requirements of regulated environments, an intersection that she identifies as underdeveloped in existing discussions.
Her professional activities have increasingly placed her in conversations beyond her immediate organizational responsibilities. Snehal was invited as a keynote speaker at the 7th Congress on Intelligent Systems (CIS 2026), organized by NIT Warangal and the Soft Computing Research Society, where her topic was AI in Pharmaceutical Quality Systems: From Automation to Accountability. She was also invited to serve as a session chair for High Performance Computing at the International Conference on High Performance Computing and Artificial Intelligence (HPCAI 2026).
These activities illustrate a wider evolution in her professional role. Rather than remaining limited to documentation production and review, she has moved toward building systems, connecting functions, contributing to professional discussions, and examining how emerging technologies can operate within regulated environments. Her own account distinguishes this work from the conventional scope of a documentation specialist, particularly through her ownership of the pilot-plant qualification framework and her external research and speaking activities.

The problem she is addressing is unlikely to become simpler. Pharmaceutical manufacturing is moving toward more connected production environments, more sophisticated technologies, and greater interest in AI-assisted processes. At the same time, regulatory expectations require organizations to demonstrate control, traceability, validation, and accountability. The future challenge will therefore not be simply whether pharmaceutical companies adopt new technologies, but whether they can integrate those technologies into quality systems without creating new gaps between what is documented, what is validated, and what actually happens in production.

Snehal Godse’s work offers one example of how that transition can be approached from within the quality function itself. By connecting equipment qualification, risk management, documentation, manufacturing readiness, and emerging AI-governance questions, her work reflects a broader shift in pharmaceutical quality: from maintaining records after the fact toward creating systems that make readiness visible throughout the lifecycle. As regulated industries continue to adopt new technologies, that distinction could become increasingly important to how pharmaceutical organizations manage both innovation and compliance.